Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients

Bruna Calsina(Spanish National Cancer Research Centre), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), María Currás-Freixes(Spanish National Cancer Research Centre), Anne‐Paule Gimenez‐Roqueplo(Délégation Paris 5), Timo Deutschbein(Klinikum Oldenburg), Felix Beuschlein(University of Zurich), Martin Faßnacht(University of Würzburg), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), Antoine Martin(Centre National de la Recherche Scientifique), Berta Obispo(Hospital Universitario Infanta Leonor), Esther Korpershoek(Radboud University Nijmegen), Judith Favier(Inserm), Massimo Mannelli(University of Florence), Tirso Pons(Spanish National Cancer Research Centre), Nicole Dölker(Centro de Investigación del Cáncer), Henri Timmers(Radboud University Nijmegen), R. Cohen(Université Paris Cité), Ronald R. de Krijger(University Medical Center Utrecht), Laura Contreras(Centro de Biología Molecular Severo Ochoa), Karel Pacák(Endocrine Society), Laurence Amar(Unit of Functional and Adaptive Biology), Laurent Vroonen(Centre Hospitalier Universitaire de Liège), Laura Remacha(Spanish National Cancer Research Centre), Alexandre Buffet(Inserm), Judith Balmañà(Vall d'Hebron Hospital Universitari), María Calatayud(Hospital Universitario 12 De Octubre), Alberto Cascón(Spanish National Cancer Research Centre), Elena Rapizzi(El.En. Group (Italy)), Susan Richter(University of Auckland), Rocío Letón, Iñaki Comino‐Méndez(Breast Cancer Now), Jorgina Satrústegui(Universidad Autónoma de Madrid)
Genetics in Medicine
July 13, 2018
Cited by 66


Related Papers